Cover Image
市場調查報告書

樹狀聚合物及高分子藥物結合物市場:2016-2026年

Dendrimers and Polymer Drug Conjugates Market, 2016 - 2026

出版商 ROOTS ANALYSIS 商品編碼 361356
出版日期 內容資訊 英文 183 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
樹狀聚合物及高分子藥物結合物市場:2016-2026年 Dendrimers and Polymer Drug Conjugates Market, 2016 - 2026
出版日期: 2016年06月15日 內容資訊: 英文 183 Pages
簡介

本報告提供藥物輸送,治療及診斷的重要工具-奈米載體的登場相關的總括性調查,二個奈米載體種類 - 以樹狀聚合物與高分子藥物結合物為焦點,提供市場環境,特性,應用,預測,及機會分析等。

第1章 序文

第2章 摘要整理

第3章 簡介

  • 診斷技術
  • 抗菌技術
  • 治療技術
  • 手術
  • 遺傳基因療法
  • 影像
  • 奈米載體:奈米醫學的重要工具
    • 奈米粒子
    • 奈米碳管 (CNT)
    • 高分子結合物
    • 奈米晶體
    • 樹狀聚合物
  • 奈米載體及藥物核准

    第4章 市場環境

    • 本章概要
    • 樹狀聚合物:產品清單、類型
    • 高分子藥物結合物:開發平台
      • 各開發階段
      • 疾病領域的各類型
      • 各高分子類型
      • 藥物的各類型
    • 主要企業

    第5章 樹狀聚合物:詳細的檢討

    • 樹狀聚合物的簡介
    • 樹狀聚合物的合成
    • 樹狀聚合物的特性評估
    • 樹狀聚合物的特徵
    • 樹狀聚合物的優點
    • 樹狀聚合物的應用
      • 藥物輸送
      • 球狀蛋白質的模仿體
      • 基因轉移
      • 影像、診斷
      • 溶解性促進劑
      • 電極的修正
      • 疫苗的開發
    • 樹狀聚合物的分類
    • 樹狀聚合物的種類
    • 樹狀聚合物成藥

    第6章 高分子藥物結合物:藥物簡介

    • 高分子藥物結合物的理論性根據
    • 高分子藥物結合物的設計、特性評估
    • 最常見的高分子
    • 最常見的藥物
    • 高分子藥物結合物的優點
    • 癌症、其他疾病的高分子藥物結合物
    • 高分子藥物結合物的:藥物簡介
      • Nektar Therapeutics
      • CTI BioPharma
      • Cerulean Pharma

    第7章 市場預測、機會分析

    • 本章概要
    • 高分子藥物結合物:未來的預測
      • 範圍、限制
      • 預測手法
      • 後期臨床分子
    • 樹狀聚合物:機會的領域
      • 藥物遞輸系統
      • 研究用途
      • 治療用途
      • 診斷用途

    第8章 總論

    第9章 附錄1:圖表

    第10章 附錄2:企業、機關清單

    圖表

  • 目錄
    Product Code: RA10061

    As defined by the National Nanotechnology Initiative, nanotechnology is the branch of science that deals with materials smaller than 100 nanometers. Nanomedicines are nano-sized particles that help in the diagnosis, treatment and monitoring of therapeutic agents. The discovery of several nanocarriers such as polymers, proteins, micelles, dendrimers, liposomes, emulsions, nanoparticles, each with a unique structure, has provided the drug developers with options to improve the pharmacokinetics and release properties of their existing drugs.

    Within the biomedical sector, nanocarriers have an array of therapeutic and diagnostic applications. These include drug delivery, targeted therapy, gene therapy, development of diagnostic assays, molecular imaging and a number of research applications. Specifically, drug delivery has emerged as one of the most popular applications that enhances the therapeutic efficacy of biomolecules. Several competing drug delivery approaches are being explored for their efficacy with various routes of administration.

    Dendrimers, owing to their structural flexibility, hold potential for several medical and non-medical applications; however, their use in the biomedical field is yet to be fully explored. Several academic institutes and organizations are conducting intense research to explore the therapeutic and diagnostic potential of dendrimers. With a number of commercial dendrimers-based products (both biomedical and agro-based), Starpharma is a prominent player in this domain.

    On the other hand, polymer drug conjugates is a well-established segment with several commercialized products. The current polymer drug conjugates market has over 10 approved drug candidates for a wide range of molecular targets and disease areas. Examples include (in alphabetical order) Adynovate by Baxalta, Doxil® by Pfizer / Sun Pharmaceuticals, Krystexxa® by Savient Pharmaceuticals / Crealta Pharmaceuticals, Movantik™ by AstraZeneca, Oncospar® by Enzon Pharmaceuticals, Plegridy® by Biogen. Despite an already well-established market, the field has gathered interest of several other players to explore the complete potential of polymer drug conjugates in different therapeutic areas. The clinical outcomes and the success of the current clinical molecules will decide the fate of the future market.

    The “Dendrimers and Polymer Drug Conjugates Market, 2016-2026” report delivers a comprehensive study on the emergence of nanocarriers as a significant tool for drug delivery, therapeutics and diagnostics. For the purpose of this report, we have primarily focused on the following two types of nanocarriers.

    • Dendrimers
    • Polymer drug conjugates

    Dendrimers, the nanoscale hyper-branched structures, are evolving in the healthcare sector to enhance the properties of existing therapeutic compounds as well as for introduction of novel therapeutic/diagnostic products. VivaGel® by Starpharma is a commercially available therapeutic product; in addition, transfection kits and diagnostic assays are also available. However, from a commercial perspective, market of dendrimers is still in its infancy within the biomedical sector. The domain is gradually gaining traction with several technologies and approaches being designed for improving drug release properties. In addition to drug delivery, which is the key application area, some other potential applications of dendrimers being actively pursued in research include disease diagnosis, targeted therapy, MRI imaging, tissue regeneration, cell repair and vaccine development.

    A parallel field of polymer therapeutics includes introduction of polymers with conventional drugs; these are more commonly known as polymer drug conjugates. Conjugation of drugs with polymers has demonstrated a marked improvement in their efficacy and release profiles. For the purpose of our study, we have included the molecules in the clinical/preclinical development (defined as per the Ringsdorf Model). Numerous polymer drug conjugates have already been commercialized for a wide range of therapeutic areas; our study provides an analysis of key disease areas being targeted by the developers of polymer drug conjugates. Several well-known anti-cancer drugs such as docetaxel, paclitaxel and doxorubicin have been conjugated with polymers such as PEG, HPMA and PLA to enhance their water solubility, half-life, efficacy and body clearance.

    The report assesses key drivers that have governed the evolution of polymer drug conjugates over the past several years and determines the market in a long term (2016-2026). The research, analysis and insights presented in this report include potential sales of the drugs in phase III and phase II of development. To add robustness to our forecast model, we have provided three market scenarios. The conservative, base and optimistic scenarios represent three different tracks of market evolution. In addition, we have provided a detailed discussion on the future trends and the key opportunity areas for dendrimers that are likely to shape the market in the coming years.

    All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

    Example Highlights

    • 1. Nearly 40 polymer drug conjugates are currently in clinical and preclinical stages of development; molecules in phase III and II account for nearly 19% of the pipeline while 26% is captured by molecules in phase I/II and I.
    • 2. There are several types of dendrimers being used for both commercial and research purposes in the pharmaceutical domain; the dendrimers most widely used for industry applications include PAMAM, PLL, Priostar®, Astramol®. However, with over 4000 papers published between 2006 and 2016 (as reported in PubMed), dendrimers are being extensively explored by researchers in the non-industry / academic institutes.
    • 3. With one commercialized therapeutic product (VivaGel®) and several other marketed dendrimer-based products (SuperFect®, Stratus® CS, PrioFect™, Alert Ticket™), Starpharma has emerged as a forerunner in the dendrimer market.
    • 4. Amongst the different biomedical applications that dendrimers and polymer drug conjugates serve, drug delivery holds a large opportunity. Several big pharma players as AstraZeneca, Eli Lilly, GSK's Stiefel have collaborated with dendrimer technology developers (such as DEP® Technology by Starpharma) to improve the therapeutic efficacy and drug delivery properties of their existing products. Additionally, polymer drug conjugates have expanded their focus to a broad range of diseases exploring different routes of administrations for better drug delivery.
    • 5. The polymer drug conjugates market momentum will be driven by the success of current batch of late stage clinical molecules; these primarily include NKTR-181 (by Nektar Therapeutics), NKTR-102 (by Nektar Therapeutics), CRLX101 (by Cerulean Pharma) and Opaxio™ (by CTI BioPharma).
    • 6. Specific molecules such as NKTR-181 and NKTR-102 are anticipated to achieve a block buster status in the near future. With eight molecules (two mentioned above and six others in lower stages of development) in development, Nektar Therapeutics is expected to play an important role in the market's evolution.

    Research Methodology

    Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

    The secondary sources of information include

    • Annual reports
    • Investor presentations
    • SEC filings
    • Industry databases
    • News releases from company websites
    • Government policy documents
    • Industry analysts' views

    While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

    Chapter Outlines

    Chapter 2 provides an executive summary of the report. It offers a high level view on the present scenario of dendrimers and polymer drug conjugates and where they are headed in the mid to long term.

    Chapter 3 provides a general introduction to nanotechnology with a detailed discussion on its applications in the biopharmaceutical industry. This chapter discusses the various types of nanocarriers that have revolutionized drug delivery and other biomedical applications.

    Chapter 4 includes information on nearly 40 polymer drug conjugates that are being evaluated in different stages of development (both clinical and preclinical/discovery). In this chapter, we have identified the companies that are active in this market and conducted a detailed pipeline analysis including information on type of polymers, type of drugs, most commonly targeted indications and the phase of development. In addition, we have provided a list of the different classes of dendrimers highlighting their developer, core molecules and surface groups.

    Chapter 5 provides an in-depth introduction to dendrimers. In this chapter, we have captured the most popular dendrimers used for development of diagnostics, therapeutics and other biomedical products; these are accompanied with detailed information on their structure, research applications and detailed product profiles of the commercialized products.

    Chapter 6 comprises of a comprehensive discussion on the advantages, applications and target disease areas of polymer drug conjugates. In addition, the chapter gives detailed profiles of phase III and phase II molecules including information of their developer, clinical trials and primary/secondary endpoints.

    Chapter 7 offers a comprehensive view on the market forecast of polymer drug conjugates measuring the opportunity in the next ten years. Due to the uncertainty surrounding some of the key assumptions, we have presented three different evolution scenarios for the overall market. In addition, we have presented a qualitative analysis of the opportunity areas of dendrimers highlighting their future potential.

    Chapter 8 summarizes the overall report. In this chapter, we have provided a recap of the key take aways and our overall opinion on where the market is headed in the mid-long term.

    Chapter 9 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

    Chapter 10 is an appendix, which provides a list of companies and organizations mentioned in the report.

    Table of Contents

    1. PREFACE

    • 1.1. Scope of the Report
    • 1.2. Research Methodology
    • 1.3. Chapter Outlines

    2. EXECUTIVE SUMMARY

    3. INTRODUCTION

    • 3.1. The Concept of Nanotechnology
    • 3.2. Nanomedicine: A Potential Platform for Therapeutic Applications
    • 3.3. Applications of Nanomedicine
      • 3.3.1. Drug Delivery
      • 3.3.2. Diagnostic Techniques
      • 3.3.3. Anti-Microbial Techniques
      • 3.3.4. Therapeutic Techniques
      • 3.3.5. Surgery
      • 3.3.6. Gene Therapy
      • 3.3.7. Imaging
    • 3.4. Nanocarriers: Important Tools for Nanomedicine
      • 3.4.1. Nanoparticles
      • 3.4.2. Carbon Nanotubes (CNTs)
      • 3.4.3. Polymer Conjugates
      • 3.4.4. Nanocrystals
      • 3.4.5. Dendrimers
    • 3.5. Nanocarriers and Drug Approvals

    4. MARKET LANDSCAPE

    • 4.1. Chapter Overview
    • 4.2. Dendrimers: Product List and Classes
    • 4.3. Polymer Drug Conjugates: Development Pipeline
      • 4.3.1. Distribution by Phase of Development
      • 4.3.2. Distribution by Type of Disease Area
      • 4.3.3. Distribution by Type of Polymer
      • 4.3.4. Distribution by Type of Drug
    • 4.3.5. Leading Players of the Industry

    5. DENDRIMERS: A DETAILED REVIEW

    • 5.1. An Introduction to Dendrimers
    • 5.2. Synthesis of Dendrimers
      • 5.2.1. Divergent Mode of Synthesis
      • 5.2.2. Convergent Mode of Synthesis
    • 5.3. Characterization of Dendrimers
      • 5.3.1. Spectroscopic Techniques
      • 5.3.2. Microscopy
      • 5.3.3. Size Exclusion Chromatography
      • 5.3.4. Other Techniques
    • 5.4. Properties of Dendrimers
    • 5.5. Advantages of Dendrimers
    • 5.6. Applications of Dendrimers
      • 5.6.1. Drug Delivery
      • 5.6.2. Mimics of Globular Proteins
      • 5.6.3. Gene Transfection
      • 5.6.4. Imaging and Diagnostics
      • 5.6.5. Solubility Enhancers
      • 5.6.6. Modification of Electrodes
      • 5.6.7. Development of Vaccines
    • 5.7. Classification of Dendrimers
    • 5.8. Types of Dendrimers
    • 5.9. Commercialized Dendrimers
      • 5.9.1. PAMAM/Starburst®
        • 5.9.1.1. Specifications
        • 5.9.1.2. Structure and Synthesis
        • 5.9.1.3. Properties
        • 5.9.1.4. Products Based on PAMAM
        • 5.9.1.5. PAMAM: Application in Biopharmaceuticals
      • 5.9.2. Poly-L-Lysine (PLL) Dendrimers (Multiple Antigen Peptide Dendrimers)
        • 5.9.2.1. Specifications
        • 5.9.2.2. Structure
        • 5.9.2.3. Products Based on PLL Dendrimers
      • 5.9.3. Priostar® Dendrimers (Frechet Type Dendrimers)
        • 5.9.3.1. Specifications
        • 5.9.3.2. Priostar®: Applications
        • 5.9.3.3. Products Based on Priostar® Dendrimers
      • 5.9.4. Astramol® (Polypropylenimine (PPI) Dendrimer)
        • 5.9.4.1. Specifications

    6. POLYMER DRUG CONJUGATES: DRUG PROFILES

    • 6.1. The Rationale of Polymer Drug Conjugates
    • 6.2. Designing and Characterization of Polymer Drug Conjugates
    • 6.3. Most Common Polymers
    • 6.4. Most Common Drugs
    • 6.5. Advantages of Polymer Drug Conjugates
    • 6.6. Polymer Drug Conjugates in Oncology and Other Diseases
    • 6.7. Polymer Drug Conjugates: Drug Profiles
      • 6.7.1. Nektar Therapeutics
        • 6.7.1.1. Company Overview
        • 6.7.1.2. Product Profile: NKTR-102 / EtirinotecanPegol
        • 6.7.1.3. Product Profile: NKTR-181
      • 6.7.2. CTI BioPharma
        • 6.7.2.1. Company Overview
        • 6.7.2.2. Product Profile: Opaxio™
      • 6.7.3. Cerulean Pharma
        • 6.7.3.1. Company Overview
        • 6.7.3.2. Product Profile: CRLX101

    7. MARKET FORECAST AND OPPORTUNITY ANALYSIS

    • 7.1. Chapter Overview
    • 7.2. Polymer Drug Conjugates: Future Projections
      • 7.2.1. Scope and Limitations
      • 7.2.2. Forecast Methodology
      • 7.2.3. Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario)
        • 7.2.3.1. NKTR-118 (Nektar Therapeutics)
        • 7.2.3.2. NKTR-102 (Nektar Therapeutics)
        • 7.2.3.3. CRLX101 (Cerulean Pharma)
        • 7.2.3.4. Opaxio™ (CTI BioPharma)
    • 7.3. Dendrimers: Opportunity Areas
      • 7.3.1. Drug Delivery Systems
      • 7.3.2. Research Applications
      • 7.3.3. Therapeutic Applications
      • 7.3.4. Diagnostic Applications

    8. CONCLUSION

    • 8.1. The Evolving Era of Polymer Therapeutics Offers Significant Promise to the Pharmaceuticals Market
    • 8.2. Amongst all the Applications, Drug Delivery Holds a Large Opportunity
    • 8.3. The Dendrimer Market is Yet to Unveil itsPotential in the Biomedical Industry
    • 8.4. Polymer Drug Conjugates are Being Exploited for Numerous Therapeutic Areas
    • 8.5. With Success of the Already Commercialized Drugs, the Next Generation of Polymer Drug Conjugates are Poised to Witness an Accelerated Growth

    9. APPENDIX 1: TABULATED DATA

    10. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

    List of Figures:

    • Figure 3.1: Application of Nanomedicines
    • Figure 3.2: Nanomedicine Drug Delivery: Applications in Key Therapeutic Areas
    • Figure 3.3: Challenges Associated with Drug Delivery in Nanotechnology
    • Figure 3.4: Classification of Nanocarriers
    • Figure 3.5: Properties of Carbon Nanotubes
    • Figure 3.6: Properties of Dendrimers
    • Figure 4.1: Pipeline Analysis: Distribution by Phase of Development
    • Figure 4.2: Pipeline Analysis: Distribution by Type of Disease Area
    • Figure 4.3: Pipeline Analysis: Distribution by Type of Polymer
    • Figure 4.4: Pipeline Analysis: Distribution by Type of Drug
    • Figure 4.5: Polymer Drug Conjugates: Key Players
    • Figure 5.1: Dendrimers: Advantages
    • Figure 5.2: Dendrimer versus Linear Polymers
    • Figure 5.3: Dendrimers: Classification
    • Figure 5.4: Dendrimers: Types
    • Figure 5.5: SuperFect® Transfection Reagent: Applications
    • Figure 5.6: SuperFect® Transfection Reagent: Protocol
    • Figure 5.7: Polyfect® Transfection Reagent: Protocol
    • Figure 5.8: PrioFect™: Clinical and Non-Clinical Applications
    • Figure 5.9: NanoJuice®Transfection Kit: Advantages
    • Figure 6.1: Polymer Drug Conjugates: Ringsdorf Model
    • Figure 6.2: Polymer Drug Conjugates: Advantages
    • Figure 6.3: Application of Polymer Drug Conjugates in Several Indications
    • Figure 6.4: Nektar Therapeutics: Annual Revenue, 2010-2015 (USD Million)
    • Figure 6.5: PEGylatedIrinotecan: NKTR-102
    • Figure 6.6: NKTR-102: Mechanism of Action
    • Figure 6.7: Advantages of NKTR-102 over Irinotecan
    • Figure 7.1: Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario)
    • Figure 7.2: Polymer Drug Conjugates Market: Share of Lead Molecules in 2026 (USD Million, %)
    • Figure 7.3: NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
    • Figure 7.4: NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
    • Figure 7.5: NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
    • Figure 7.6: NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
    • Figure 7.7: CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
    • Figure 7.8: CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
    • Figure 7.9: Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
    • Figure 7.10: Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
    • Figure 7.11: Collaboration Based Revenues: Illustrative Future Projections
    • Figure 8.1: Polymer Therapeutics versus Conventional Therapeutics
    • Figure 8.2: Polymer Drug Conjugates: Emerging Therapeutic Areas
    • Figure 8.3: Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2017, 2021, 2026

    List of Tables:

    • Table 3.1: Approved Nanocrystal Drugs
    • Table 3.2: List of Commercialized Nanomedicines
    • Table 4.1: Dendrimers: Product List and Classes
    • Table 4.2: Polymer Drug Conjugates: Development Pipeline
    • Table 5.1: List of Drugs Loaded in Dendrimers
    • Table 5.2: List of Commercialized Dendrimers
    • Table 5.3: Dendritech: List of PAMAM Dendrimers
    • Table 5.4: Stratus® CS: Type of Biomarkers
    • Table 5.5: SuperFect™ Transfection Reagent: Product Details
    • Table 5.6: PolyFect™ Transfection Reagent: Product Details
    • Table 5.7: PolyFect™ Transfection Reagent: Product Details
    • Table 5.8: PAMAM: Biotherapeutic Applications
    • Table 5.9: VivaGel®: Current Status of Development
    • Table 5.10: VivaGel®: Current Status of Development
    • Table 5.11: VivaGel®: Clinical Trial Endpoints
    • Table 5.12: Gadomer-17: Product Specifications
    • Table 5.13: PPI Dendrimers: Price and Quantity
    • Table 6.1: Approved Polymer Drug Conjugates
    • Table 6.2: Polymer Drug Conjugates: Profiled Drugs
    • Table 6.3: NKTR-102: Current Status of Development
    • Table 6.4: NKTR-102: Clinical Trials
    • Table 6.5: NKTR-102: Phase II Clinical Trial Endpoints (Breast Cancer, Ovarian Cancer, Colorectal Cancer, Lung Cancer)
    • Table 6.6: NKTR-102: Phase II Clinical Trial Endpoints (Glioma, Solid Tumors)
    • Table 6.7: NKTR-102 versus TPC: Adverse Events
    • Table 6.8: NKTR-181: Current Status of Development
    • Table 6.9: NKTR-181: Clinical Trials
    • Table 6.10: NKTR-181: Clinical Trials
    • Table 6.11: Opaxio™: Current Status of Development
    • Table 6.12: Opaxio™: Clinical Studies
    • Table 6.13: Opaxio™: Clinical Trial Endpoints for Ovarian Epithelial, Peritoneal and Fallopian Tube Cancer
    • Table 6.14: Opaxio™: Clinical Trial Endpoints for Other Indications
    • Table 6.15: CRLX101: Current Status of Development
    • Table 6.16: CRLX101: Clinical Studies
    • Table 6.17: CRLX101: Clinical Trial Endpoints (Phase II Studies)
    • Table 6.18: CRLX101: Clinical Trial Endpoints (Phase I/II Studies)
    • Table 7.1: Polymer Drug Conjugates: Market Potential of Candidates
    • Table 7.2: NKTR-181: Target Patient Population
    • Table 7.3: NKTR-102: Target Patient Population
    • Table 7.4: CRLX101: Target Patient Population
    • Table 7.5: Opaxio™: Target Patient Population
    • Table 7.6: Dendrimers: Opportunity Areas
    • Table 7.7: Drug Delivery Systems: Example List
    • Table 7.8: Commercialized Dendrimer-Based Kits
    • Table 9.1: Pipeline Analysis: Distribution by Phase of Development
    • Table 9.2: Pipeline Analysis: Distribution by Type of Disease Area
    • Table 9.3: Pipeline Analysis: Distribution by Type of Polymer
    • Table 9.4: Pipeline Analysis: Distribution by Type of Drug
    • Table 9.5: Polymer Drug Conjugates: Key Players
    • Table 9.6: Nektar Therapeutics: Annual Revenue, 2010-2015 (USD Million)
    • Table 9.7: Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario)
    • Table 9.8: Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Optimistic Scenario)
    • Table 9.9: Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Conservative Scenario)
    • Table 9.10: Polymer Drug Conjugates Market: Share of Lead Molecules in 2026 (USD Million, %)
    • Table 9.11: NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
    • Table 9.12: NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
    • Table 9.13: NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
    • Table 9.14: NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
    • Table 9.15: NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
    • Table 9.16: NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
    • Table 9.17: NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
    • Table 9.18: NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
    • Table 9.19: NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
    • Table 9.20: NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
    • Table 9.21: NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
    • Table 9.22: NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
    • Table 9.23: CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
    • Table 9.24: CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
    • Table 9.25: CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
    • Table 9.26: CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
    • Table 9.27: CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
    • Table 9.28: CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
    • Table 9.29: Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
    • Table 9.30: Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
    • Table 9.31: Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
    • Table 9.32: Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
    • Table 9.33: Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
    • Table 9.34: Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
    • Table 9.35: Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2017, 2021, 2026

    Listed Companies

    The following companies and organizations have been mentioned in this report.

    • 1. 3S Bio
    • 2. Abeona Therapeutics
    • 3. Abramson Cancer Center
    • 4. Access Pharmaceuticals
    • 5. Adama
    • 6. Ajinomoto Althea
    • 7. Allergan
    • 8. Alliance for Clinical Trials in Oncology
    • 9. Allied Corporation
    • 10. Althea Technologies
    • 11. Altus Pharmaceuticals
    • 12. Amgen
    • 13. Ansell Limited
    • 14. Arsenal Medical
    • 15. ASCEND Therapeutics
    • 16. Ascendis Pharma
    • 17. Aspen Pharmacare
    • 18. AstraZeneca
    • 19. Baxalta
    • 20. Belrose Pharma
    • 21. Beth Israel Deaconess Medical Center
    • 22. BIND Sciences
    • 23. Biogen
    • 24. Brown University
    • 25. Cancer Therapeutics
    • 26. Carlina Technologies
    • 27. Cellular Therapeutics
    • 28. Cerulean Pharma
    • 29. City of Hope Medical Center
    • 30. Clemson University
    • 31. Colcom
    • 32. Cosmo Pharmaceuticals
    • 33. Crealta Pharmaceuticals
    • 34. CTI BioPharma
    • 35. CytImmune
    • 36. Dade Behring
    • 37. Dana-Farber Cancer Institute
    • 38. Dartmouth-Hitchcock Medical Center
    • 39. DelSiTech
    • 40. Delta-Fly Pharma
    • 41. Dendritech Nanotechnologies
    • 42. Dow Chemical
    • 43. Durect Corporation
    • 44. Edge Therapeutics
    • 45. Eli Lilly
    • 46. EMD Biosciences
    • 47. Enzon Pharmaceuticals
    • 48. Eunice Kennedy Shriver National Institute of Child Health and Human Development
    • 49. Eyetech
    • 50. Ferring
    • 51. Flamel Technologies
    • 52. Genentech
    • 53. GlaxoSmithKline
    • 54. Gowan
    • 55. Gynecologic Oncology Group Foundation
    • 56. JenKem Technology
    • 57. Landec
    • 58. Lipotek
    • 59. M.D. Anderson Cancer Center
    • 60. MakhteshimAgan
    • 61. Massachusetts General Hospital
    • 62. Massachusetts Institute of Technology
    • 63. Memorial Sloan Kettering Cancer Center
    • 64. Merck
    • 65. Mersana Therapeutics
    • 66. Michigan Nanotechnology Institute for Medicine and Biological Sciences
    • 67. Mountain View Pharmaceuticals
    • 68. Mylan
    • 69. Nanovector
    • 70. National Cancer Institute
    • 71. National Heart and Lung Institute
    • 72. National Institute of Allergy and Infectious Diseases
    • 73. National Institutes of Health
    • 74. National Institute of Mental Health
    • 75. National Institute on Drug Abuse
    • 76. National Nanotechnology Initiative
    • 77. Nektar Therapeutics
    • 78. NeuroNano Pharma
    • 79. Novartis
    • 80. Nufarm
    • 81. Oakwood Laboratories
    • 82. Octoplus
    • 83. Okamoto Industries
    • 84. Ontario Institute for Cancer Research
    • 85. Peptineo
    • 86. Pfizer
    • 87. PG-TXL
    • 88. Pharmacia and Upjohn Company
    • 89. PolyActiva
    • 90. Polymer Factory
    • 91. PolyPid
    • 92. ProCore Bio Med
    • 93. ProLynx
    • 94. pSivida
    • 95. Qiagen
    • 96. Reckitt Benckiser
    • 97. Rexahn Pharmaceuticals
    • 98. Roche
    • 99. Roswell Park Cancer Institute
    • 100. Sagent Pharmaceuticals
    • 101. Sanofi-Aventis
    • 102. Santarus
    • 103. Savient Pharmaceuticals
    • 104. Schering Plough
    • 105. Serina Therapeutics
    • 106. Shire
    • 107. Sigma Aldrich
    • 108. Sitka Biopharma
    • 109. Sloan-Kettering Institute for Cancer Research
    • 110. Sonoran Biosciences
    • 111. Stanford Cancer Institute
    • 112. Stanford University
    • 113. Starpharma
    • 114. Stiefel Laboratories
    • 115. Sun Pharma
    • 116. SUNY Upstate Medical University
    • 117. SyMO-Chem
    • 118. Teva Pharmaceutical
    • 119. The Methodist Hospital System
    • 120. The State University of New York
    • 121. UCB Pharma
    • 122. UNC Lineberger Comprehensive Cancer Center
    • 123. University of Chicago
    • 124. University of Colorado Boulder
    • 125. University of Glasgow
    • 126. University of Illinois
    • 127. University of Maryland
    • 128. University of Pennsylvania
    • 129. University of Southern California
    • 130. University of Washington
    • 131. US Army Research Laboratory
    • 132. Weihai CY
    • 133. World Health Organization
    • 134. Wyss Institute
    • 135. XstalBio
    • 136. Yamanouchi Pharmaceutical
    Back to Top